• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

新型 2-(1-金刚烷羰酰胺基)噻吩衍生物的合成。作为治疗皮肤炎症性疾病的潜在药物的选择性大麻素类型 2 (CB2) 受体激动剂。

Synthesis of novel 2-(1-adamantanylcarboxamido)thiophene derivatives. Selective cannabinoid type 2 (CB2) receptor agonists as potential agents for the treatment of skin inflammatory disease.

机构信息

Dipartimento di Biotecnologie, Chimica e Farmacia, Università degli Studi di Siena, Via Aldo Moro 2, 53100, Siena, Italy.

Endocannabinoid Research Group, Istituto di Chimica Biomolecolare, Consiglio Nazionale delle Ricerche, Via dei Campi Flegrei 34, 80078, Pozzuoli (Napoli), Italy.

出版信息

Eur J Med Chem. 2019 Jan 1;161:239-251. doi: 10.1016/j.ejmech.2018.09.070. Epub 2018 Oct 13.

DOI:10.1016/j.ejmech.2018.09.070
PMID:30359820
Abstract

A set of CB2R ligands, based on the thiophene scaffold, was synthesized and evaluated in in vitro assays. Compounds 8c-i, k, l, bearing the 3-carboxylate and 2-(adamantan-1-yl)carboxamido groups together with apolar alkyl/aryl substituents at 5-position or at 4- and 5-positions of the thiophene ring possess high CB2R affinity at low nanomolar concentration, good receptor selectivity, and agonistic functional activity. The full agonist 8g, showing the best balance between receptor affinity and selectivity, was tested in vitro in an experimental model of allergic contact dermatitis and proved to be able to block the release of MCP-2 in HaCaT cells at 10 μM concentration.

摘要

一组基于噻吩骨架的 CB2R 配体被合成并在体外试验中进行了评估。化合物 8c-i、k、l,带有 3-羧酸根和 2-(金刚烷-1-基)羧酰胺基,以及在噻吩环的 5-位或 4-和 5-位上带有非极性烷基/芳基取代基,在低纳摩尔浓度下具有高 CB2R 亲和力、良好的受体选择性和激动性功能活性。完全激动剂 8g 在过敏性接触性皮炎的实验模型中进行了体外测试,证明在 10 µM 浓度下能够阻断 MCP-2 在 HaCaT 细胞中的释放,其在受体亲和力和选择性之间达到了最佳平衡。

相似文献

1
Synthesis of novel 2-(1-adamantanylcarboxamido)thiophene derivatives. Selective cannabinoid type 2 (CB2) receptor agonists as potential agents for the treatment of skin inflammatory disease.新型 2-(1-金刚烷羰酰胺基)噻吩衍生物的合成。作为治疗皮肤炎症性疾病的潜在药物的选择性大麻素类型 2 (CB2) 受体激动剂。
Eur J Med Chem. 2019 Jan 1;161:239-251. doi: 10.1016/j.ejmech.2018.09.070. Epub 2018 Oct 13.
2
Synthesis, in vitro and in vivo evaluation of 1,3,5-triazines as cannabinoid CB2 receptor agonists.1,3,5-三嗪作为大麻素CB2受体激动剂的合成、体外及体内评价
Eur J Pharm Sci. 2015 Jan 25;67:85-96. doi: 10.1016/j.ejps.2014.11.003. Epub 2014 Nov 14.
3
Structure-activity relationships of thiazole and benzothiazole derivatives as selective cannabinoid CB2 agonists with in vivo anti-inflammatory properties.噻唑和苯并噻唑衍生物作为选择性大麻素 CB2 激动剂的构效关系,具有体内抗炎特性。
Eur J Med Chem. 2019 Oct 15;180:154-170. doi: 10.1016/j.ejmech.2019.07.002. Epub 2019 Jul 2.
4
Discovery of novel Tetrahydrobenzo[b]thiophene and pyrrole based scaffolds as potent and selective CB2 receptor ligands: The structural elements controlling binding affinity, selectivity and functionality.发现新型基于四氢苯并[b]噻吩和吡咯的支架作为有效且选择性的CB2受体配体:控制结合亲和力、选择性和功能的结构要素。
Eur J Med Chem. 2016 Oct 21;122:619-634. doi: 10.1016/j.ejmech.2016.07.012. Epub 2016 Jul 9.
5
Novel Triazolopyrimidine-Derived Cannabinoid Receptor 2 Agonists as Potential Treatment for Inflammatory Kidney Diseases.新型三唑并嘧啶衍生的大麻素受体2激动剂作为炎症性肾脏疾病的潜在治疗方法
ChemMedChem. 2016 Jan 19;11(2):179-89. doi: 10.1002/cmdc.201500218. Epub 2015 Jul 21.
6
Synthesis and biological evaluation of (3',5'-dichloro-2,6-dihydroxy-biphenyl-4-yl)-aryl/alkyl-methanone selective CB2 inverse agonist.(3',5'-二氯-2,6-二羟基-联苯-4-基)-芳基/烷基-甲酮选择性CB2反向激动剂的合成与生物学评价
Bioorg Med Chem. 2015 Sep 1;23(17):5390-401. doi: 10.1016/j.bmc.2015.07.057. Epub 2015 Jul 29.
7
Structure-affinity relationships and pharmacological characterization of new alkyl-resorcinol cannabinoid receptor ligands: Identification of a dual cannabinoid receptor/TRPA1 channel agonist.新型烷基间苯二酚大麻素受体配体的结构-亲和力关系及药理学特性:一种双重大麻素受体/TRPA1通道激动剂的鉴定
Bioorg Med Chem. 2014 Sep 1;22(17):4770-83. doi: 10.1016/j.bmc.2014.07.006. Epub 2014 Jul 12.
8
Synthesis and evaluation of 2-amido-3-carboxamide thiophene CB₂ receptor agonists for pain management.合成及评价 2-酰胺基-3-羧酰胺噻吩 CB₂ 受体激动剂用于疼痛管理。
Bioorg Med Chem Lett. 2012 Apr 1;22(7):2604-8. doi: 10.1016/j.bmcl.2012.01.121. Epub 2012 Feb 4.
9
Discovery of 7-oxopyrazolo[1,5-a]pyrimidine-6-carboxamides as potent and selective CB(2) cannabinoid receptor inverse agonists.发现 7-氧代吡唑并[1,5-a]嘧啶-6-甲酰胺类化合物作为强效和选择性 CB(2) cannabinoid 受体反向激动剂。
J Med Chem. 2013 Jun 13;56(11):4482-96. doi: 10.1021/jm400182t. Epub 2013 Jun 4.
10
Structure-kinetic relationship studies of cannabinoid CB receptor agonists reveal substituent-specific lipophilic effects on residence time.构效关系研究表明,大麻素 CB 受体激动剂的取代基具有特定的亲脂性,影响其停留时间。
Biochem Pharmacol. 2018 Jun;152:129-142. doi: 10.1016/j.bcp.2018.03.018. Epub 2018 Mar 21.

引用本文的文献

1
Combined experimental and computational investigation of vildagliptin: spectroscopy, electronic structure, MD and Docking to EGFR, VEGFR2, and HER2 anticancer targets.维格列汀的实验与计算联合研究:光谱学、电子结构、分子动力学以及与表皮生长因子受体(EGFR)、血管内皮生长因子受体2(VEGFR2)和人表皮生长因子受体2(HER2)抗癌靶点的对接
J Comput Aided Mol Des. 2025 Aug 13;39(1):66. doi: 10.1007/s10822-025-00646-9.
2
Design, Synthesis, and Biological Evaluation of Novel Hydroxytyrosol Derivatives as Protectors for Vascular Endothelium Against Lipid Overload.新型羟基酪醇衍生物作为血管内皮抗脂质过载保护剂的设计、合成及生物学评价
Drug Des Devel Ther. 2025 Apr 1;19:2433-2452. doi: 10.2147/DDDT.S500670. eCollection 2025.
3
The Impact of the CB Cannabinoid Receptor in Inflammatory Diseases: An Update.
CB 大麻素受体在炎症性疾病中的作用:最新研究进展。
Molecules. 2024 Jul 18;29(14):3381. doi: 10.3390/molecules29143381.
4
Discovery of Potent and Selective CB2 Agonists Utilizing a Function-Based Computational Screening Protocol.利用基于功能的计算筛选方案发现有效且选择性的 CB2 激动剂。
ACS Chem Neurosci. 2023 Nov 1;14(21):3941-3958. doi: 10.1021/acschemneuro.3c00580. Epub 2023 Oct 12.
5
The Magic Methyl and Its Tricks in Drug Discovery and Development.神奇的甲基及其在药物研发中的作用
Pharmaceuticals (Basel). 2023 Aug 15;16(8):1157. doi: 10.3390/ph16081157.
6
Systematic Modification of the Substitution Pattern of the 7-Hydroxy-5-oxopyrazolo[4,3-]pyridine-6-carboxamide Scaffold Enabled the Discovery of New Ligands with High Affinity and Selectivity for the Cannabinoid Type 2 Receptor.系统修饰 7-羟基-5-氧代吡唑并[4,3-]吡啶-6-甲酰胺支架的取代模式,发现了对大麻素 2 型受体具有高亲和力和选择性的新型配体。
Molecules. 2023 Jun 24;28(13):4958. doi: 10.3390/molecules28134958.
7
Cannabinoid Compounds as a Pharmacotherapeutic Option for the Treatment of Non-Cancer Skin Diseases.大麻素化合物作为治疗非癌症皮肤疾病的一种药物治疗选择。
Cells. 2022 Dec 16;11(24):4102. doi: 10.3390/cells11244102.
8
Rational drug design of CB2 receptor ligands: from 2012 to 2021.CB2受体配体的合理药物设计:2012年至2021年
RSC Adv. 2022 Dec 8;12(54):35242-35259. doi: 10.1039/d2ra05661e. eCollection 2022 Dec 6.
9
Small molecule compounds with good anti-inflammatory activity reported in the literature from 01/2009 to 05/2021: a review.文献报道的 2009 年 1 月至 2021 年 5 月具有良好抗炎活性的小分子化合物:综述。
J Enzyme Inhib Med Chem. 2021 Dec;36(1):2139-2159. doi: 10.1080/14756366.2021.1984903.
10
Pharmacological Properties, Therapeutic Potential and Molecular Mechanisms of JWH133, a CB2 Receptor-Selective Agonist.CB2受体选择性激动剂JWH133的药理特性、治疗潜力及分子机制
Front Pharmacol. 2021 Jul 30;12:702675. doi: 10.3389/fphar.2021.702675. eCollection 2021.